Page 11 - B Cell News Today

Researchers identified that among healthy young adults, the development of SARS-CoV-2 triggered memory B cell and antibody reactions were equivalent following mildly symptomatic or asymptomatic infections.

Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, describe a different way to build a COVID-19 vaccine, one that would, in theory, remain effective against new and emerging variants and could be taken as a pill, by inhalation or other delivery methods.

The SARS-CoV-2-specific B- and T-cell response post-COVID-19 primary and booster vaccination in primary antibody deficient patients.

Researchers examined immune reactions to SARS-CoV-2)among B cell-depleted autoimmune patients who concomitantly administered glucocorticoids.

A recent study discovered antibody footprints strongly correlated with immunopathology of SARS-CoV-2 infection using a new B cell epitope identification approach

Researchers reported a class switch in SARS-CoV-2-specific antibodies due to repeated mRNA vaccinations.

A new study describes the immunologic parameters associated with protection from COVID-19.

In a recent study published in the journal Science Immunology, researchers in the United States described a rare anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) three antibody cocktail IMM-BCP-01.

A recent study posted to the bioRxiv* preprint server supports using mosaic sarbecovirus receptor-binding domain (RBD)-nanoparticles to discover therapeutic pan-variant and pan-sarbecovirus monoclonal antibodies (mAbs) and to induce mAbs by vaccination.

In recent research posted to the bioRxiv* preprint server, investigators confirmed that human immunodeficiency virus (HIV) co-infection alters B cell reaction in coronavirus disease 2019 (COVID-19).